The headline is broadly defensible, but the qualifications matter. Effect sizes vary by population, the strongest claims rest on shorter trials, and credible voices push back on how it's typically framed.
here's this drug that blocks CB1 and CB2 receptors which are the cannabinoid receptors in the human body which can be activated by both exogenous cannabinoids THC or others or the products of linoleic acid breakdown 2ag anandamide potentially and that these are a signal for hyperphasia and that you can abut that you can abrogate hyperfasia by blocking those receptors
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.
they discovered in animal models that it seems to be just as effective if you get a endocannabinoid receptor blocker that only works in the gut